Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

Official Title: “An Open Label, Non Randomized , One Sequence, Add-On Study to Investigate the Effects of PTK787/ZK 222584 on the Pharmacokinetics and Pharmacodynamics of Warfarin at Steady-States in Cancer Patients”

RATIONALE: Vatalanib may stop the growth of tumor cells by stopping blood flow to the tumor.

Warfarin may be effective in preventing the formation of blood clots in patients who are undergoing treatment for advanced solid tumors.

PURPOSE: This phase I trial is studying how well giving warfarin together with vatalanib works in treating patients with advanced solid tumors.

OBJECTIVES:

Primary - Determine the acute and chronic changes in INR in patients with advanced solid tumors treated with low-dose warfarin and vatalanib.

Secondary - Determine the steady-state pharmacokinetics of this regimen in these patients. - Determine the safety and tolerability of this regimen in these patients.

OUTLINE: This is a nonrandomized, open-label, multicenter study. - Pharmacokinetic (PK) phase: Patients receive oral low-dose warfarin once daily on days 1-14 and oral vatalanib once daily, 1 hour before warfarin administration, on days 2-14 in the absence of disease progression or unacceptable toxicity. - Continuation phase: Patients not experiencing a drug interaction in the PK phase continue to receive oral vatalanib and oral low-dose warfarin once daily. Patients experiencing a drug interaction (INR > 2.0) in the PK phase receive oral vatalanib alone once daily. Continuation therapy continues indefinitely in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Intervention(s) in this Clinical Trial

• Drug: vatalanib
• Drug: warfarin

Primary Measures

• To evaluate acute and chronic changes in INR when Warfarin is co-administered with PTK787/ZK 222584
  • Safety Issue?: No

Secondary Measures

• To evaluate the steady state pharmacokinetics of (R) and (S) Warfarin when co-administered with PTK787/ZK 222584
  • Safety Issue?: No
• To evaluate the safety and tolerability of low dose warfarin when co-administered with PTK787/ZK 222584
  • Safety Issue?: Yes

Inclusion Criteria:

• Histologically confirmed advanced solid tumor
• Progressed despite standard therapy OR no known standard therapy exists
• - Currently receiving OR a candidate for prophylactic low-dose warfarin (1 mg/day)
• INR ≤ 1.4
• Must be an extensive metabolizer of CYP2C9 (at least 1 wild type allelle: *1)
• 18 and over
• Hemoglobin ≥ 9 g/dL
• AST and ALT ≤ 3 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Albumin ≥ 3.0 g/dL
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative
• Creatinine ≤ 1.5 ULN OR
• Creatinine clearance > 50 mL/min
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• More than 14 days since prior anticancer chemotherapy
• More than 14 days since prior anticancer hormonal therapy
• More than 14 days since prior anticancer radiotherapy
• More than 14 days since other prior anticancer therapy
• More than 30 days since prior investigational drugs
• No ethanol for 2 days prior to and for the first 17 days of study treatment

Exclusion Criteria:

• No poor metabolizers of CYP2C9 (2 alleles of either *2 or *3)
• brain metastases
• history of or active coagulation disorders
• significant risk for bleeding
• uncontrolled high blood pressure (BP), defined as diastolic BP > 90 mm Hg or systolic
• BP > 140 mm Hg
• history of cerebral or aortic aneurysm
• pregnant or nursing
• recent history or evidence of drug or alcohol abuse
• active peptic ulcer disease or gastrointestinal bleeding
• contraindication or allergy to warfarin or related compounds
• risk for adverse events related to prolonged PT/PTT due to warfarin administration
• other medical condition that would preclude study participation
• concurrent chemotherapy
• concurrent hormonal therapy
• concurrent radiotherapy
• other concurrent CYP2C9 substrates or inhibitors
• concurrent CYP3A4 inducers or inhibitors
• concurrent food or dietary supplement known to alter the metabolism of CYP3A4 (e.g., grapefruit or Hypericum perforatum [St. John's wort])

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: University of California, Los Angeles Other

Overall Clinical Trial Officials and Contacts

Joel R. Hecht, MD Principal Investigator Jonsson Comprehensive Cancer Center  

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00091299

Study ID Number: CDR0000386239

ClinicalTrials.gov Identifier: NCT00091299

Health Authority: United States: Food and Drug Administration

Clinical trial summary from the National Cancer Institute's PDQ® database